DISIT BIOTECH

Pioneering drug research to transform radiation-related damage into new therapeutic opportunities — improving cancer patients' life quality and expectancy.

Our Science

How are we leveraging the power of peptide-based therapies to pioneer new solutions? Discover how these therapies are driving groundbreaking treatments.

Mission

Generation of groundbreaking medicines and advance clinical care through peptide innovative solutions, empowering patients to face pathologies with hope and dignity

Vision

To set the standard in innovative therapies that address unmet medical needs, transforming patients' lives through technological excellence and a solid commitment to health equity.

Values

Empathy: We are driven by the desire to alleviate the suffering of patients and their families.
Innovation: We foster creativity and research to discover new solutions.
Collaboration: We work as a team with researchers, physicians, and society, advancing toward a shared goal.
Integrity: We act with transparency and ethics in every decision we make.
Excellence: We are committed to achieving the highest standards in the development of quality treatments.

Pipeline

DISIT's pipelines drive innovation in biotechnology, encompassing groundbreaking research, preclinical studies, and clinical development. Focused on precision and quality, we deliver cutting-edge solutions to advance science and improve lives, ensuring progress through every stage of discovery and development.

DISIT Biotech focused on generating clinical solutions based on TGF-β inhibition for unmeet oncological complications with a pharmaceutical ingredient with potential for multiple therapies.

Committed to innovation and excellence, on the path of developing clinical solutions that impact globally on the quality and life expectancy of oncology patients.

News and Articles

We stay proactive and think big. Stay informed about our latest research news.

P144 a Transforming Growth Factor Beta Inhibitor Peptide, Generates Antifibrogenic Effects in a Radiotherapy Induced Fibrosis Model

A synthetic peptide from transforming growth factor β type III receptor inhibits liver fibrogenesis in rats with carbon tetrachloride liver injury

Transforming growth factor beta (TGF-β) activity in immuno-oncology studies

P144 a Transforming Growth Factor Beta Inhibitor Peptide, Generates Antifibrogenic Effects in a Radiotherapy Induced Fibrosis Model

A synthetic peptide from transforming growth factor β type III receptor inhibits liver fibrogenesis in rats with carbon tetrachloride liver injury

Transforming growth factor beta (TGF-β) activity in immuno-oncology studies

Awards & Grants

Award Innovative Project 2022 at Innova Health Congress

Torres Quevedo Program for the Recruitment of PhD Researchers

SiloAceleraBio Acceleration Program for Startups and Innovative Projects in Life Sciences

Innovative Pyme Award - Valid until 2028

Aid for the development of new innovative technology-base companies (start-up) 2023

References

"Really impressed by DISIT Biotech’s strategic vision and research results! A company with the potential to become a true game-changer in the field of radiotherapy."

"Interacting with DISIT Biotech has been an inspiring experience. Their team stands out not only for their expertise but also for their genuine warmth and willingness to support collaborative efforts in the biotech sector."

"It has been a pleasure collaborating with DISIT Biotech since its early days. Their professionalism and commitment to excellence make them an outstanding and motivating client."

"I deeply value the scientific rigor and integrity demonstrated by DISIT Biotech. Their commitment to excellence and ethical values in research is truly commendable. "